Table 2. Analytical comparison of... | American Society of Hematology

Table 2.

Analytical comparison of clinical trial characteristics across groups A, B, and C

	Group A, n	Group B, n	Group C, n	Total, N	P*
Phase					<.001†
1/2 or 2	32	223	24	279
2/3 or 3	14	21	3	38
Status					.971
Completed	20	116	12	148
Ongoing or recruiting	11	60	7	78
Terminated, withdrawn, unknown, or not yet recruiting	15	68	8	91
Disease focus					<.001†
MDS only	44	148	19	211
AML, CMML, or other hematologic malignancies	2	96	8	106
Therapy used					.004†
HMAs	7	67	12	86
Novel agents	5	30	2	37
Growth factors	17	29	2	48
Oral chemotherapy	13	76	9	98
Others	4	42	2	48

	Group A, n	Group B, n	Group C, n	Total, N	P*
Phase					<.001†
1/2 or 2	32	223	24	279
2/3 or 3	14	21	3	38
Status					.971
Completed	20	116	12	148
Ongoing or recruiting	11	60	7	78
Terminated, withdrawn, unknown, or not yet recruiting	15	68	8	91
Disease focus					<.001†
MDS only	44	148	19	211
AML, CMML, or other hematologic malignancies	2	96	8	106
Therapy used					.004†
HMAs	7	67	12	86
Novel agents	5	30	2	37
Growth factors	17	29	2	48
Oral chemotherapy	13	76	9	98
Others	4	42	2	48

Fisher’s exact test.

Denotes significance at P < .05.